Institute of Environmental Science and Research
A Genome-Wide Association Study of Gout in People of European Ancestry.pdf (71.08 kB)

A genome-wide association study of gout in people of European ancestry

Download (71.08 kB)
posted on 2019-04-04, 21:26 authored by Tony R. Merriman, Murray Cadzow, Marilyn E. Merriman, Amanda Phipps-Green, Ruth Topless, Abhishek Abhishek, Linda A. Bradbury, RUSSELL BUCHANANRUSSELL BUCHANAN, Katie Cremin, Janak de Zoysa, Michael Doherty, Catherine Hill, Tom W.J. Huizinga, Tim Jansen, M. Janssen, Leo A.B. Joosten, Fina Kurreeman, Susan Lester, Frederic Lioté, Donia Macartney-Coxson, Hirotaka Matsuo, Geraldine M McCarthy, Sally McCormick, Rinki Murphy, Karel Pavelka, Fernando Perez-Ruiz, Juan Puig, Timothy RDJ Radstake, Philip Riches, Maureen Rischmueller, Edward Roddy, Malcolm Smith, Eli A. Stahl, Blanka Stibůrková, Richard Stubbs, Anne-Kathrin Tausche, Rosario Torres, Rob Walker, Kentaro Yamamoto, Matthew A. Brown, Hyon K. Choi, Nicola Dalbeth, Jeffrey N. Miner, Alexander So, Lisa K. Stamp, Tanya Major

Background/Purpose: Genome wide association studies (GWAS) have provided considerable insight into the molecular control of urate levels. However, less is known about the progression from asymptomatic hyperuricemia to gout. Our aim was to conduct a GWAS for gout in people of European ancestry using the largest number of cases of gout to date.

Methods: This GWAS (7,431 cases and 105,631 controls) was comprised of three data sets: a mixed New Zealand (NZ), Eurogout, and Ardea Biosciences group (3,961 cases; 1,547 controls; genotyped using the Illumina CoreExome v24 array, 547,644 markers), a composite set from the Health Professionals Follow-Up (HPFS) and NursesÕ Health Studies (NHS) (1,038 cases; 1,095 controls; genotyped using the Illumina OmniExpress v12 array, 730,525 markers), and UK Biobank (2,432 cases; 102,989 controls; genotyped using an Affymetrix Axiom array, 820,967 markers). The UK Biobank genotypes were imputed to ~73.3M SNPs. Neither the NZ/Eurogout/Ardea nor NHS/HPFS genotype sets were imputed. Markers found within all three data sets (234,062) were identified and associated with gout (adjusted for sex and age), within each data set separately, using PLINK v1.9. An inverse-variance weighted meta-analysis of the results was then performed using the meta v4.4 package within R v3.2.3. The overall genome inflation factor was 0.90.

Results: There were nine loci with experiment-wide significance (0.05/234,062; P < 2×10-7) for association with gout: ABCG2 (OR=1.77), SLC2A9 (OR=1.69), GCKR (OR=1.24), MLXIPL (OR=1.18), SLC17A1-A4 (OR=1.22), SLC16A9 (OR=1.18), SLC22A12 (OR=1.16), PDZK1 (OR=1.16), TRIM46 (OR=1.15). All nine of these loci have been previously associated with serum urate levels in genome-wide studies with the urate-increasing alleles also associated with increased risk of gout in this study.

Conclusion: Our data emphasize the central importance of genetic involvement in serum urate levels, compared to the genetic involvement in MSU crystal formation, or the innate immune response, in determining gout.


Usage metrics



    Ref. manager